Compounds > cangrelor

cangrelor and Coronary-Occlusion

cangrelor has been researched along with Coronary-Occlusion* in 3 studies

Trials

1 trial(s) available for cangrelor and Coronary-Occlusion

ArticleYear
Characteristics of dyspnoea and associated clinical outcomes in the CHAMPION PHOENIX study.
    Thrombosis and haemostasis, 2017, 06-02, Volume: 117, Issue:6

    Dyspnoea may be induced by some reversibly-binding P2Y

    Topics: Adenosine Monophosphate; Aged; Clopidogrel; Coronary Occlusion; Double-Blind Method; Drug-Related Side Effects and Adverse Reactions; Dyspnea; Female; Humans; Intention to Treat Analysis; Male; Middle Aged; Percutaneous Coronary Intervention; Receptors, Purinergic P2Y12; Survival Analysis; Ticlopidine; Treatment Outcome; Withholding Treatment

2017

Other Studies

2 other study(ies) available for cangrelor and Coronary-Occlusion

ArticleYear
Discontinuation of both cangrelor and ticagrelor because of severe dyspnea during primary angioplasty.
    Journal of cardiovascular medicine (Hagerstown, Md.), 2021, 04-01, Volume: 22, Issue:4

    Topics: Adenosine Monophosphate; Aged; Anxiety; Chest Pain; Coronary Angiography; Coronary Occlusion; Drug Substitution; Drug-Eluting Stents; Drug-Related Side Effects and Adverse Reactions; Dyspnea; Electrocardiography; Humans; Inferior Wall Myocardial Infarction; Male; Percutaneous Coronary Intervention; Purinergic P2Y Receptor Antagonists; ST Elevation Myocardial Infarction; Ticagrelor; Treatment Outcome; Withholding Treatment

2021
Cangrelor-supported primary percutaneous coronary intervention in a patient with cardiogenic shock due to left main acute occlusion.
    Journal of cardiovascular medicine (Hagerstown, Md.), 2020, Volume: 21, Issue:8

    Topics: Adenosine Monophosphate; Coronary Occlusion; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Shock, Cardiogenic; Treatment Outcome

2020